286 related articles for article (PubMed ID: 34509406)
1. Health Status Predicts Short- and Long-Term Risk of Composite Clinical Outcomes in Acute Heart Failure.
Hu D; Liu J; Zhang L; Bai X; Tian A; Huang X; Zhou K; Gao M; Ji R; Miao F; Li J; Li W; Ge J; He G; Li J
JACC Heart Fail; 2021 Dec; 9(12):861-873. PubMed ID: 34509406
[TBL] [Abstract][Full Text] [Related]
2. Association of Cardiac Biomarkers With the Kansas City Cardiomyopathy Questionnaire in Patients With Chronic Kidney Disease Without Heart Failure.
Tummalapalli SL; Zelnick LR; Andersen AH; Christenson RH; deFilippi CR; Deo R; Go AS; He J; Ky B; Lash JP; Seliger SL; Soliman EZ; Shlipak MG; Bansal N;
J Am Heart Assoc; 2020 Jul; 9(13):e014385. PubMed ID: 32578483
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Kansas City Cardiomyopathy Questionnaire and Minnesota Living With Heart Failure Questionnaire in Predicting Heart Failure Outcomes.
Yee D; Novak E; Platts A; Nassif ME; LaRue SJ; Vader JM
Am J Cardiol; 2019 Mar; 123(5):807-812. PubMed ID: 30587373
[TBL] [Abstract][Full Text] [Related]
4. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
[TBL] [Abstract][Full Text] [Related]
5. Stress hyperglycemia ratio as a prognostic indicator for long-term adverse outcomes in heart failure with preserved ejection fraction.
Mohammed AQ; Luo Y; Wang K; Su Y; Liu L; Yin G; Zhang W; Alifu JJ; Mareai RM; Mohammed AA; Xu Y; Abdu FA; Che W
Cardiovasc Diabetol; 2024 Feb; 23(1):67. PubMed ID: 38350936
[TBL] [Abstract][Full Text] [Related]
6. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
Januzzi JL; Ahmad T; Mulder H; Coles A; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Mark DB; Piña IL; Passmore G; Whellan DJ; Cooper LS; Leifer ES; Desvigne-Nickens P; Felker GM; O'Connor CM
J Am Coll Cardiol; 2019 Sep; 74(9):1205-1217. PubMed ID: 31466618
[TBL] [Abstract][Full Text] [Related]
7. N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure.
Arzilli C; Aimo A; Vergaro G; Ripoli A; Senni M; Emdin M; Passino C
Eur J Prev Cardiol; 2018 May; 25(8):889-895. PubMed ID: 29569494
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Pocock SJ; Ferreira JP; Packer M; Zannad F; Filippatos G; Kondo T; McMurray JJV; Solomon SD; Januzzi JL; Iwata T; Salsali A; Butler J; Anker SD
Eur J Heart Fail; 2022 Oct; 24(10):1869-1878. PubMed ID: 35796209
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score.
Scrutinio D; Ammirati E; Guida P; Passantino A; Raimondo R; Guida V; Sarzi Braga S; Pedretti RF; Lagioia R; Frigerio M; Catanzaro R; Oliva F
Int J Cardiol; 2013 Oct; 168(3):2120-6. PubMed ID: 23395457
[TBL] [Abstract][Full Text] [Related]
11. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.
Piña IL; Camacho A; Ibrahim NE; Felker GM; Butler J; Maisel AS; Prescott MF; Williamson KM; Claggett BL; Desai AS; Solomon SD; Januzzi JL;
JACC Heart Fail; 2021 Jan; 9(1):42-51. PubMed ID: 33189630
[TBL] [Abstract][Full Text] [Related]
12. Echocardiography, natriuretic peptides, and risk for incident heart failure in older adults: the Cardiovascular Health Study.
Kalogeropoulos AP; Georgiopoulou VV; deFilippi CR; Gottdiener JS; Butler J;
JACC Cardiovasc Imaging; 2012 Feb; 5(2):131-40. PubMed ID: 22340818
[TBL] [Abstract][Full Text] [Related]
13. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
[TBL] [Abstract][Full Text] [Related]
14. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
[TBL] [Abstract][Full Text] [Related]
15. Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Butler J; Spertus JA; Hellkamp AS; Vaduganathan M; DeVore AD; Albert NM; Duffy CI; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
JAMA Cardiol; 2021 May; 6(5):522-531. PubMed ID: 33760037
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
[TBL] [Abstract][Full Text] [Related]
17. Serial cardiac biomarker assessment in adults with congenital heart disease hospitalized for decompensated heart failure
Aldweib N; Elia EG; Brainard SB; Wu F; Sleeper LA; Rodriquez C; Valente AM; Landzberg MJ; Singh M; Mullen M; Opotowsky AR
Int J Cardiol Congenit Heart Dis; 2022 Mar; 7():. PubMed ID: 35463849
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM
J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
20. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials.
Pokharel Y; Khariton Y; Tang Y; Nassif ME; Chan PS; Arnold SV; Jones PG; Spertus JA
JAMA Cardiol; 2017 Dec; 2(12):1315-1321. PubMed ID: 29094152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
